Ryanodex is owned by Eagle Pharms.
Ryanodex contains Dantrolene Sodium.
Ryanodex has a total of 5 drug patents out of which 3 drug patents have expired.
Expired drug patents of Ryanodex are:
Ryanodex was authorised for market use on 22 July, 2014.
Ryanodex is available in for suspension;intravenous dosage forms.
Ryanodex can be used as for use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk..
The generics of Ryanodex are possible to be released after 30 June, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9884044||EAGLE PHARMS||Treatment using dantrolene|| |
(7 months ago)
|US8604072||EAGLE PHARMS||Treatment using dantrolene|| |
(6 months ago)
|US8110225||EAGLE PHARMS||Treatment using dantrolene|| |
(a month ago)
|US8685460||EAGLE PHARMS||Treatment using dantrolene|| |
(12 days from now)
|US7758890||EAGLE PHARMS||Treatment using dantrolene|| |
(2 years from now)
Market Authorisation Date: 22 July, 2014
Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.
Dosage: FOR SUSPENSION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic